NCT01891227View on ClinicalTrials.gov

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 9, 2013

Primary Completion Date

March 15, 2018

Study Completion Date

March 15, 2018

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).

DRUG

Bendamustine

Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).

Trial Locations (8)

8036

Universitätsklinik f. Frauenheilkunde und Geburtshilfe, Klin. Abt. f. Gynäkologie, Graz

Universitätsklinik f. Innere Medizin, Klin.Abt. f. Onkologie, Graz

A-6807

Hämatologie und Onkologie/Interne E, LKH Feldkirch, Feldkirch

A-6020

Univ.-Klinik f. Frauenheilkunde; Klinische Abt. f. Gynäkologie u. Geburtshilfe, Innsbruck

A-4010

KH Barmh. Schwestern Linz, Innere Medizin I Hämatologie/Onkologie, Linz

A-4021

Kepler Universitätsklinikum, Med Campus III, Klinik f. Interne 3 - Schwerpunkt Hämatologie u. Onkologie, Linz

A-5020

Universitätsklinik für Innere Medizin III, Salzburg

A-4400

Landeskrankenhaus Steyr, Interne Medizin II, Steyr

All Listed Sponsors
lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER

NCT01891227 - Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer | Biotech Hunter | Biotech Hunter